含奥沙利铂化学治疗方案对Ⅱ期结直肠癌患者肝纤维化的影响(3)
参考文献
[1] Bray F,Ferlay J,Soerjomataram I,Siegel RL, Torre LA,Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimatesof Incidence and Mortalitv Worldwide for 36 Cancers in 185Countries. CA Cancer J Clin. 2018, 68(6):394-424.
[2] AndreT,Boni C,Mounedji-Boudiaf L,Navarro M,Taberner。J, Hickish T,TophamC,Zaninelli M,Clingan P,BridgewaterJ, Tabah-Fisch I, de Cramont A. Oxaliplatin, fluorouracil, andleucovorin as adjuvant treatment for colon c.ancer.N Engl J Med,2004, 350( 23):2343-2351.
, http://www.100md.com
[3] 林鋒,李勇.手术联合围手术期FOLFOX4化疗与单纯手术对可切除结直肠癌肝转移治疗的多中心随机对照临床试验.循证医学,2009.9(3):147-149.
[4] GillS, Loprinzi CL, Sargent DJ, Thome SD. Alberts SR, HallerDG, Benedetti J,Francini G,Shepherd LE, Francois Seitz J,Labianca R,Chen W. Cha SS. Heldebrant MP, Goldberg RMPooled analysis of fluorouracil-based adjuvant therapy for stageII andⅢcolon cancer: who henefits and by how much?J ClinOncol, 2004. 22( lO): 1797-1806.
[5] Schrag D,Rifas-Shiman S,Saltz L,Bach PB, Begg CB.Adjuvant chemotherapy use for medicare heneficiaries with stageII colon cancer.J Clin Oncol. 2002. 20( 19):3999-4005.
, 百拇医药
[6] Robinson SM, Mann J,Manas DM. Mann DA. WhiteSA. An experimental study to identify the potential role ofpharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury. HPB, 2013. 15(8):581-587.
[7] Duwe G,Knitter S, Pesthy S,Beierle AS, Bahra M,SchmelzleM, Schmuck RB, Lohneis P,Raschzok N,Ollinger R,Sinn M,Struecker B,Sauer lM, Pratschke J, Andreou A Hepatotoxicityfollowing systemic therapy for colorectal liver metastases andthe impact of cheruotherapy-associated liver injury on outcomesafter curative liver resection. Eur J Surg Oncol, 2017, 43(9):1668-1681.
, 百拇医药
[8] Tajima H,Ohta T,Miyashita T,Nakanuma S,Matoba M,MiyataT, Sakai S, OkamotoK,MakinoI, Kinoshita J, HayashiH, Nakamura K,Oyama K,Inokuchi M,Nakagawara H,Takamura H,Kitagawa H,Fushida S,lkeda H.oxaliplatin-based chemotherapy induces extravasated platelet aggregationinthe liver. Mol Clin Oncol, 2015. 3 ( 3 ) : 555-558.
[9] Boursier J, Vergniol J. Guillet A . Hinart JB. Lannes A. Le BailB, Michalak S. Chermak F. Bertrais S. Foucher J. Oberti F.Charbonnier M . Fouchard-Hubert I. Rousselet MC . Cales P. deLedinghen V. Diagnostic accuracy and prognostic significance ofblood fibrosis tests and liver stiffness measurement by FibroScanin non-alcoholic fatty liver disease. J Hepatol. 2016, 65 ( 3 ) :570-578.
[10]Wai cr, Creenson JK. Fontana RJ. Kalbfleisch JD. MarreroJA, Conjeevaram HS, Lok AS. A simple noninvasive index canpredict both significant fibrosis and cirrhosis in patients withchronic hepatitis C. Hepatology, 2010, 38 ( 2 ) : 518-526., 百拇医药(梁承华 郑晓明 张亚琴 雷普润 蔡梓凯 魏波)
[1] Bray F,Ferlay J,Soerjomataram I,Siegel RL, Torre LA,Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimatesof Incidence and Mortalitv Worldwide for 36 Cancers in 185Countries. CA Cancer J Clin. 2018, 68(6):394-424.
[2] AndreT,Boni C,Mounedji-Boudiaf L,Navarro M,Taberner。J, Hickish T,TophamC,Zaninelli M,Clingan P,BridgewaterJ, Tabah-Fisch I, de Cramont A. Oxaliplatin, fluorouracil, andleucovorin as adjuvant treatment for colon c.ancer.N Engl J Med,2004, 350( 23):2343-2351.
, http://www.100md.com
[3] 林鋒,李勇.手术联合围手术期FOLFOX4化疗与单纯手术对可切除结直肠癌肝转移治疗的多中心随机对照临床试验.循证医学,2009.9(3):147-149.
[4] GillS, Loprinzi CL, Sargent DJ, Thome SD. Alberts SR, HallerDG, Benedetti J,Francini G,Shepherd LE, Francois Seitz J,Labianca R,Chen W. Cha SS. Heldebrant MP, Goldberg RMPooled analysis of fluorouracil-based adjuvant therapy for stageII andⅢcolon cancer: who henefits and by how much?J ClinOncol, 2004. 22( lO): 1797-1806.
[5] Schrag D,Rifas-Shiman S,Saltz L,Bach PB, Begg CB.Adjuvant chemotherapy use for medicare heneficiaries with stageII colon cancer.J Clin Oncol. 2002. 20( 19):3999-4005.
, 百拇医药
[6] Robinson SM, Mann J,Manas DM. Mann DA. WhiteSA. An experimental study to identify the potential role ofpharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury. HPB, 2013. 15(8):581-587.
[7] Duwe G,Knitter S, Pesthy S,Beierle AS, Bahra M,SchmelzleM, Schmuck RB, Lohneis P,Raschzok N,Ollinger R,Sinn M,Struecker B,Sauer lM, Pratschke J, Andreou A Hepatotoxicityfollowing systemic therapy for colorectal liver metastases andthe impact of cheruotherapy-associated liver injury on outcomesafter curative liver resection. Eur J Surg Oncol, 2017, 43(9):1668-1681.
, 百拇医药
[8] Tajima H,Ohta T,Miyashita T,Nakanuma S,Matoba M,MiyataT, Sakai S, OkamotoK,MakinoI, Kinoshita J, HayashiH, Nakamura K,Oyama K,Inokuchi M,Nakagawara H,Takamura H,Kitagawa H,Fushida S,lkeda H.oxaliplatin-based chemotherapy induces extravasated platelet aggregationinthe liver. Mol Clin Oncol, 2015. 3 ( 3 ) : 555-558.
[9] Boursier J, Vergniol J. Guillet A . Hinart JB. Lannes A. Le BailB, Michalak S. Chermak F. Bertrais S. Foucher J. Oberti F.Charbonnier M . Fouchard-Hubert I. Rousselet MC . Cales P. deLedinghen V. Diagnostic accuracy and prognostic significance ofblood fibrosis tests and liver stiffness measurement by FibroScanin non-alcoholic fatty liver disease. J Hepatol. 2016, 65 ( 3 ) :570-578.
[10]Wai cr, Creenson JK. Fontana RJ. Kalbfleisch JD. MarreroJA, Conjeevaram HS, Lok AS. A simple noninvasive index canpredict both significant fibrosis and cirrhosis in patients withchronic hepatitis C. Hepatology, 2010, 38 ( 2 ) : 518-526., 百拇医药(梁承华 郑晓明 张亚琴 雷普润 蔡梓凯 魏波)